Result of Placing

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is pleased to announce that, further to the announcement made at 5.00pm on 8 October 2026 regarding the Placing (the “Launch Announcement”), it has conditionally raised gross proceeds of £8.5 million by way of a placing of 4,250,000,000 Placing Shares with existing and new investors at the Issue Price of 0.20 pence per Placing Share.

The Placing was increased to £8.5 million to accommodate additional interest received through the ABB, with strong support from both existing and new intuitional investors. Allocations will be confirmed to Placees as soon as practicable today.

Singer Capital Markets and Oberon Capital are acting as joint brokers and joint bookrunners for and on behalf of the Company in respect of the Placing.

Highlights

The Company has conditionally raised, in aggregate, gross proceeds of £8.5 million at the Issue Price of 0.20 pence.

The Issue Price represents a discount of approximately 11.1% to the closing middle market price of 0.225 pence per Ordinary Share on 30 September 2026, being the latest dealing day prior to trading in the Company’s shares being suspended when the Company entered a Capital Access Window

The Placing will comprise the issue of approximately 1,683,000,000 Firm Placing Shares and, 2,567,000,000 Conditional Placing Shares that will be issued subject to Shareholders passing the relevant resolutions at the General Meeting;

The Company will announce later today the launch of a retail offer to existing and new Shareholders via the Winterflood Retail Access Platform to raise up to £250,000 at the Issue Price “WRAP Retail Offer”)

Director participation in the Placing

The following Directors have participated in the Placing as set out below (the "Director’s Participation").

*Assuming full take up of the WRAP Retail Offer

Admission, settlement and dealings

Application will be made to the London Stock Exchange for the 1,683,000,000 Firm Placing Shares to be admitted to trading on the AIM market of the London Stock Exchange ("Admission").

Settlement for the Firm Placing Shares and First Admission is expected to take place on or around 8.00 a.m. on 13 October 2026 or, in each case, such later time and/or date as the Joint Brokers and the Company agree (being in any event no later than 8.00 a.m. on 23 October 2026).

Immediately following First Admission, the issued share capital of the Company will comprise 3,970,311,687 Ordinary Shares. Each Ordinary Share has one voting right and no Ordinary Shares are held in treasury. Accordingly, immediately following First Admission, the total number of voting rights in the Company will be 3,970,311,687. From First Admission, this figure may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Settlement for the Conditional Placing Shares and the WRAP Retail Offer Shares, and Second Admission, is expected to take place on or around 8.00 a.m. on 28 October 2026 or, in each case, such later time and/or date as the Joint Brokers and the Company agree (being in any event no later than 8.00 a.m. on 30 November 2026).

The Placing Shares and the WRAP Retail Offer Shares, when issued, will be credited as fully paid and will rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Information to Distributors

UK Product Governance Requirements

EU Product Governance Requirements